Learn more →
Back to Expert Scholars
medical-oncology / medical-oncologyPediatric Neuro-Oncology

Eric Bouffet

埃里克·布费

MD

🏢The Hospital for Sick Children (SickKids), Toronto(多伦多病童医院)🌐Canada

Head of Paediatric Haematology/Oncology, Neuro-Oncology Program Director儿科血液/肿瘤科主任,神经肿瘤项目主任

63
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Professor Eric Bouffet is a world leader in pediatric neuro-oncology originally trained in France and now heading SickKids' program in Toronto. He pioneered BRAF-targeted therapy for pediatric low-grade glioma and led pivotal trials transforming survival for children with brain tumors.

Share:

🧪Research Fields 研究领域

Pediatric Oncology儿科肿瘤学
Neuro-Oncology神经肿瘤学
Brain Tumors脑肿瘤
BRAF InhibitorsBRAF抑制剂

🎓Key Contributions 主要贡献

BRAF-Targeted Therapy in Pediatric Glioma

Led foundational clinical work establishing BRAF/MEK inhibition as effective targeted therapy for BRAF V600E-mutated pediatric low-grade gliomas, offering chemotherapy-free options.

Medulloblastoma Risk Stratification

Advanced molecular subgroup characterization of medulloblastoma and contributed to reduced-dose radiotherapy strategies for average-risk patients, decreasing long-term neurotoxicity.

Global Pediatric Neuro-Oncology Leadership

Co-led the International Society of Paediatric Oncology (SIOPE/SIOP) brain tumor committees, harmonizing international treatment protocols and advancing cooperative trial design.

Representative Works 代表性著作

[1]

Vemurafenib in Pediatric Patients with BRAF V600E–Mutated High-Grade Glioma

Pediatric Blood & Cancer (2018)

Clinical evidence for BRAF V600E inhibitor activity in pediatric high-grade glioma, supporting targeted therapy in a previously chemorefractory population.

[2]

Dabrafenib plus trametinib in pediatric BRAF V600–mutant low-grade glioma

New England Journal of Medicine (2023)

LOGGIC/FIREFLY-1 trial demonstrating superior response rates with BRAF+MEK inhibition over chemotherapy in pediatric BRAF-mutant low-grade glioma.

[3]

Molecular subgroups of medulloblastoma: long-term outcomes and treatment implications

Lancet Oncology (2016)

Long-term survival analysis defining prognostic impact of WNT, SHH, Group 3 and Group 4 medulloblastoma subgroups with implications for risk-adapted therapy.

🏆Awards & Recognition 奖项与荣誉

🏆SIOPE Distinguished Achievement Award
🏆Canadian Cancer Society Research Innovation Award
🏆Pediatric Brain Tumor Foundation Courage Award
🏆International Society of Paediatric Oncology (SIOP) Leadership Recognition

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 埃里克·布费 的研究动态

Follow Eric Bouffet's research updates

留下邮箱,当我们发布与 Eric Bouffet(The Hospital for Sick Children (SickKids), Toronto)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment